FDA Accepts uniQure’s Huntington’s Gene Therapy for Priority Review, Decision Due May 2027
After earlier setbacks, FDA grants Priority Review to uniQure’s AMT-130 as a potential first disease-modifying Huntington’s treatment.
After earlier setbacks, FDA grants Priority Review to uniQure’s AMT-130 as a potential first disease-modifying Huntington’s treatment.
Leerink cut Bristol Myers and raised Zentalis. Barclays lowered uniQure. Cantor upgraded Rezolute. New Buy calls on Ovid, Maravai, and Regenxbio.
AMT-130 slowed Huntington’s 44% at four years, but the result lost statistical significance after stronger three-year data. Stock falls as FDA review begins.
William Blair restarts QURE coverage with a $73 estimate, citing a clearer FDA path for AMT-130 in Huntington’s and cash funding into 2030.
uniQure receives positive FDA feedback for accelerated approval of its one-time gene therapy AMT-130 for Huntington’s disease. BLA submission planned for Q3 2026.
FDA may pick Dr. Hemmati to lead CBER, which could speed up vaccine and biotech drug approvals, but decision is not final.